The US FDA has approved iptacopan for the treatment of adults with complement 3 glomerulopathy (C3G) to reduce proteinuria. Iptacopan was first approved by the FDA in 2023 for treating adults with paroxysmal nocturnal hemoglobinuria and reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression. Clinical evidence In a clinical trial involving 74 patients with C3G, iptacopan significantly reduced the 24-hour urine protein-to-creatinine ratio (UPCR) by 35% over six months compared to a placebo.
Notably, patients treated with iptacopan had sevenfold higher odds of achieving a 50% or greater reduction in 24-hour UPCR or an improved estimated glomerular filtration rate (£ 15% reduction) compared to the placebo. Dosage and administration Available as capsules 200 mg orally twice daily with or without food Contraindications Severe…
